Immune Checkpoint Blockade

How does cancer “work”?

And why do some cancers respond to immunotherapies, while others do not? Rutgers Cancer Institute has performed groundbreaking research to answering these questions by studying the tumor microenvironment. Under the leadership of Dr. Eileen White, research at Rutgers Cancer Institute has focused on identification of mechanisms of response to immune checkpoint blockade (ICB), a type of immunotherapy where treatments are used to “block” the immune defenses of certain tumor cells, allowing the body’s T cells, in turn, to kill the tumor cells. By examining patients who have an exceptional response to ICB, Rutgers Cancer Institute researchers have identified several novel mechanisms underlying that response.

These mechanisms include mutations in a gene called DNA polymerase epsilon (POLE) that introduce mistakes during DNA replication. These mistakes elevate tumor mutational burden (TMB), which is the number of mutations, or changes, that the DNA of a tumor cell has. The number and locations of mutations in the DNA of the tumor cell help identify which therapies are more likely to produce changes in the tumor, thereby increasing the ability of the immune system to identify and eliminate the tumor cells. The higher the number of mutations, the higher the TMB, which makes tumor cells more visible to the immune system and more likely that ICB treatment will work.
 


 

These pivotal findings have led to new clinical trials in several types of cancer assessing elevated TMB due to mutations in POLE, the related DNA polymerase POLD1, or BRCA1/2 (which elevate TMB by blocking repair of DNA mutations), as an indicator of response to ICB therapy.

There have already been success stories from these clinical trials, including that of Marcia Bird. Ms. Bird had endometrial cancer, which was treated with surgery, chemotherapy, and radiation. After several clear scans, she got the devastating news that the cancer had metastasized to her neck and pelvic lymph nodes. Following analysis of her specific endometrial cancer, her physicians found high PD-L1 expression that made her eligible for a clinical trial of pembrolizumab, an immune checkpoint inhibitor. The treatment was an impressive success, and within months her tumors shrank. Using the Precision Medicine Program at Rutgers Cancer Institute, researchers analyzed Ms. Bird’s tumor samples and found a POLE mutation, which occurs in about 10 percent of endometrial cancers, and a high TMB, potentially explaining her tumor’s vulnerability to ICB. This unique finding was studied further in the laboratory, which revealed that mutations in POLE render tumors particularly responsive to immunotherapy. The groundbreaking discovery of POLE mutations led to a new immunotherapy treatment paradigm.

Innovation Inspiring Hope

This research at Rutgers Cancer Institute has already paved the way for FDA approval of a tumor vaccine for treatment of Merkel cell carcinoma (a type of skin cancer), representing a victory of research in action. Key questions remain, however, including: What is the mechanism of response to ICB? Why do some tumors with high TMB fail to respond to ICB? Why do some tumors with low TMB respond to ICB? Can combining ICB with other agents improve anti-tumor immune responses?

It is the passion and goal of the Rutgers Cancer Institute Duncan and Nancy MacMillan Cancer Immunology and Metabolism Center of Excellence to answer these questions. We continue to probe into the microenvironment of tumor cells, to unlock the secrets to how tumor cells work and how to manipulate these processes to discover new, effective treatments for all types of cancers. Our innovation is laying the groundwork for providing new hope to cancer patients across the globe.

 

Related News

        

Find Out More